Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Identifieur interne : 001796 ( PubMed/Corpus ); précédent : 001795; suivant : 001797Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
Auteurs : E R Marcotte ; A. Chugh ; R K Mishra ; R L JohnsonSource :
- Peptides [ 0196-9781 ] ; 1998.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors), Animals, Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Dopamine (metabolism), Hormone Antagonists (pharmacology), MPTP Poisoning, MSH Release-Inhibiting Hormone (analogs & derivatives), MSH Release-Inhibiting Hormone (pharmacology), Male, Mice, Mice, Inbred C57BL, Nerve Degeneration (prevention & control), Neuroprotective Agents (pharmacology), Neurotoxins (antagonists & inhibitors), Neurotoxins (toxicity), Parkinson Disease, Secondary (metabolism), Parkinson Disease, Secondary (prevention & control), Pyrrolidinones (pharmacology), Receptors, Dopamine (drug effects).
- MESH :
- chemical , analogs & derivatives : MSH Release-Inhibiting Hormone.
- chemical , antagonists & inhibitors : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Neurotoxins.
- drug effects : Corpus Striatum, Receptors, Dopamine.
- metabolism : Corpus Striatum, Dopamine, Parkinson Disease, Secondary.
- chemical , pharmacology : Hormone Antagonists, MSH Release-Inhibiting Hormone, Neuroprotective Agents, Pyrrolidinones.
- prevention & control : Nerve Degeneration, Parkinson Disease, Secondary.
- chemical , toxicity : Neurotoxins.
- Animals, Disease Models, Animal, MPTP Poisoning, Male, Mice, Mice, Inbred C57BL.
Abstract
3(R)-[(2(S)-Pyrrolidinyl-carbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF-1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.
PubMed: 9493876
Links to Exploration step
pubmed:9493876Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)</title><author><name sortKey="Marcotte, E R" sort="Marcotte, E R" uniqKey="Marcotte E" first="E R" last="Marcotte">E R Marcotte</name><affiliation><nlm:affiliation>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Chugh, A" sort="Chugh, A" uniqKey="Chugh A" first="A" last="Chugh">A. Chugh</name></author><author><name sortKey="Mishra, R K" sort="Mishra, R K" uniqKey="Mishra R" first="R K" last="Mishra">R K Mishra</name></author><author><name sortKey="Johnson, R L" sort="Johnson, R L" uniqKey="Johnson R" first="R L" last="Johnson">R L Johnson</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1998">1998</date><idno type="RBID">pubmed:9493876</idno><idno type="pmid">9493876</idno><idno type="wicri:Area/PubMed/Corpus">001796</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001796</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)</title><author><name sortKey="Marcotte, E R" sort="Marcotte, E R" uniqKey="Marcotte E" first="E R" last="Marcotte">E R Marcotte</name><affiliation><nlm:affiliation>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Chugh, A" sort="Chugh, A" uniqKey="Chugh A" first="A" last="Chugh">A. Chugh</name></author><author><name sortKey="Mishra, R K" sort="Mishra, R K" uniqKey="Mishra R" first="R K" last="Mishra">R K Mishra</name></author><author><name sortKey="Johnson, R L" sort="Johnson, R L" uniqKey="Johnson R" first="R L" last="Johnson">R L Johnson</name></author></analytic><series><title level="j">Peptides</title><idno type="ISSN">0196-9781</idno><imprint><date when="1998" type="published">1998</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors)</term><term>Animals</term><term>Corpus Striatum (drug effects)</term><term>Corpus Striatum (metabolism)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Hormone Antagonists (pharmacology)</term><term>MPTP Poisoning</term><term>MSH Release-Inhibiting Hormone (analogs & derivatives)</term><term>MSH Release-Inhibiting Hormone (pharmacology)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Nerve Degeneration (prevention & control)</term><term>Neuroprotective Agents (pharmacology)</term><term>Neurotoxins (antagonists & inhibitors)</term><term>Neurotoxins (toxicity)</term><term>Parkinson Disease, Secondary (metabolism)</term><term>Parkinson Disease, Secondary (prevention & control)</term><term>Pyrrolidinones (pharmacology)</term><term>Receptors, Dopamine (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>MSH Release-Inhibiting Hormone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Neurotoxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Corpus Striatum</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Dopamine</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Hormone Antagonists</term><term>MSH Release-Inhibiting Hormone</term><term>Neuroprotective Agents</term><term>Pyrrolidinones</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Nerve Degeneration</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Neurotoxins</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>MPTP Poisoning</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">3(R)-[(2(S)-Pyrrolidinyl-carbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF-1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9493876</PMID><DateCreated><Year>1998</Year><Month>04</Month><Day>13</Day></DateCreated><DateCompleted><Year>1998</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0196-9781</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>1998</Year></PubDate></JournalIssue><Title>Peptides</Title><ISOAbbreviation>Peptides</ISOAbbreviation></Journal><ArticleTitle>Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)</ArticleTitle><Pagination><MedlinePgn>403-6</MedlinePgn></Pagination><Abstract><AbstractText>3(R)-[(2(S)-Pyrrolidinyl-carbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) is a peptidomimetic analog of Pro-Leu-Gly-NH2 (PLG or MIF-1) that has previously been demonstrated to be more potent and efficacious that MIF-1 in enhancing dopamine receptor activity. Given the ability of MIF-1 to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesioning in C57 BL/6 mice, the present study was undertaken to evaluate the neuroprotective effect of PAOPA in this model. PAOPA was found to be more potent and efficacious that MIF-1 in sparing dopamine and its metabolite levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Whether the enhanced neuroprotective effect of PAOPA is due to dopamine receptor stimulation, or a result of reduced oxidative stress through normalization of dopamine turnover, remains to be determined.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marcotte</LastName><ForeName>E R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chugh</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>R K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Peptides</MedlineTA><NlmUniqueID>8008690</NlmUniqueID><ISSNLinking>0196-9781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006727">Hormone Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011760">Pyrrolidinones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>106732-52-9</RegistryNumber><NameOfSubstance UI="C067487">3-(N-prolylamine)-2-oxo-1-pyrrolidineacetamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>9083-38-9</RegistryNumber><NameOfSubstance UI="D009075">MSH Release-Inhibiting Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9P21XSP91P</RegistryNumber><NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015632" MajorTopicYN="N">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006727" MajorTopicYN="N">Hormone Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020267" MajorTopicYN="N">MPTP Poisoning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009075" MajorTopicYN="N">MSH Release-Inhibiting Hormone</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010302" MajorTopicYN="N">Parkinson Disease, Secondary</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011760" MajorTopicYN="N">Pyrrolidinones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>3</Month><Day>11</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9493876</ArticleId><ArticleId IdType="pii">S0196-9781(97)00321-5</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001796 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001796 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:9493876
|texte= Protection against MPTP treatment by an analog of Pro-Leu-Gly-NH2 (PLG, MIF-1)
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:9493876" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |